About Us

The Staphylococcus aureus bacteraemia Network Adaptive Platform Trial is an innovative trial to evaluate a range of interventions with the aim of improving outcomes for patients with Staphylococcus aureus bacteraemia (AKA bloodstream infections). 

This trial will include both adults and children.

The study includes sites from throughout Australia, New Zealand, Singapore, Canada, Israel and the UK and has the potential to include sites elsewhere in the world.

Snap Team

Co-ordinating Investigators

Meet the SNAP Team
Joshua Davis

Professor Joshua S Davis PhD, FRACP, MBBS (Hons), DTM&H, Grad Cert Pop Health. Infectious Diseases Physician and NHMRC Career Development Fellow at the University of Newcastle and the Menzies School of Health Research.

Steven Tong

Professor Steven YC Tong PhD, FRACP, MBBS (Hons), Grad Dip Epidemiol Biostats, Infectious Diseases Physician with the Victorian Infectious Diseases Service.

More News & Events

SNAP Trial News

More News
Written on
May 22, 2023

Short Course Antibiotic Therapy

Presentation by Dr Brad Spellberg, Chief Medical Officer at the Los Angeles County-University of Southern California (LAC+USC) Medical Center.

SNAP Trial Resource
Written on

Clinical trial SNAP celebrates 12-month milestone

On this day last year, the SNAP trial started recruitment. 12 months on, more than 450 participants have joined the study, already making it the second largest clinical trial for Staphylococcus aureus bloodstream infections in the world.

SNAP Trial Resource
Written on
May 25, 2022

Treatment for deadly blood infections in children to be focus of Australian-led global study

Staphylococcus aureus can cause sepsis, among other infections, and sends more than 450 Australian babies, children and teenagers to hospital annually, according to Telethon Kids Institute.

SNAP Trial Resource